PL2787345T3 - Możliwości leczenia choroby Fabry’ego - Google Patents

Możliwości leczenia choroby Fabry’ego

Info

Publication number: PL2787345T3
Authority: PL; Poland
Prior art keywords: treatment options; fabry disease; fabry; disease; options
Prior art date: 2006-05-16

Application number

PL14168748T

Other languages

English (en)

Inventor

David Lockhart

Jeff Castelli

Original Assignee

Amicus Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-16

Filing date

2007-05-16

Publication date

2016-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2787345(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-05-16 Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc

2016-08-31 Publication of PL2787345T3 publication Critical patent/PL2787345T3/pl

Links

208000024720 Fabry Disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Ecology (AREA)
Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Obesity (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL14168748T 2006-05-16 2007-05-16 Możliwości leczenia choroby Fabry’ego PL2787345T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US80108906P	2006-05-16	2006-05-16
US85363106P	2006-10-23	2006-10-23
EP07797506.8A EP2024745B1 (en)	2006-05-16	2007-05-16	Assays for diagnosing and evaluating treatment options for fabry disease
EP14168748.3A EP2787345B8 (en)	2006-05-16	2007-05-16	Treatment options for fabry disease

Publications (1)

Publication Number	Publication Date
PL2787345T3 true PL2787345T3 (pl)	2016-08-31

Family

ID=38723987

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL18197135.9T PL3457135T3 (pl)	2006-05-16	2007-05-16	Możliwości leczenia choroby fabry'ego
PL14168748T PL2787345T3 (pl)	2006-05-16	2007-05-16	Możliwości leczenia choroby Fabry’ego
PL12168451T PL2533050T6 (pl)	2006-05-16	2007-05-16	Możliwości leczenia choroby Fabry'ego

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL18197135.9T PL3457135T3 (pl)	2006-05-16	2007-05-16	Możliwości leczenia choroby fabry'ego

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL12168451T PL2533050T6 (pl)	2006-05-16	2007-05-16	Możliwości leczenia choroby Fabry'ego

Country Status (19)

Country	Link
US (9)	US7851143B2 (pl)
EP (6)	EP2533050B3 (pl)
JP (7)	JP2009537149A (pl)
AU (1)	AU2007253900A1 (pl)
CA (1)	CA2652553C (pl)
CY (3)	CY1115180T1 (pl)
DK (3)	DK3457135T3 (pl)
ES (4)	ES2573498T3 (pl)
FI (1)	FI3457135T3 (pl)
HK (1)	HK1218955A1 (pl)
HU (3)	HUE027569T2 (pl)
LT (2)	LT3457135T (pl)
LU (1)	LU93312I2 (pl)
MX (2)	MX351004B (pl)
NL (1)	NL300843I2 (pl)
PL (3)	PL3457135T3 (pl)
PT (2)	PT2533050E (pl)
SI (3)	SI2533050T1 (pl)
WO (1)	WO2007137072A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009537149A (ja)	2006-05-16	2009-10-29	アミークスセラピューティックスインコーポレイテッド	ファブリー病に対する治療の選択を診断し、評価するためのアッセイ
US9999618B2 (en)	2007-04-26	2018-06-19	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2008134628A2 (en) *	2007-04-26	2008-11-06	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) *	2008-02-12	2009-08-20	Amicus Therapeutics, Inc.	Method to predict response to pharmacological chaperone treatment of diseases
WO2009114712A2 (en) *	2008-03-12	2009-09-17	Amicus Therapeutics, Inc.	Assays for diagnosing and evaluating treatment options for pompe disease
AR079057A1 (es) *	2009-11-17	2011-12-21	Baylor Res Inst	Triaosilceramida urinaria (gb3) como marcador de enfermedad cardiaca
AU2011223706A1 (en) *	2010-03-05	2012-09-20	Baylor Research Institute	Involvement of androgen/androgen receptor pathway in Fabry disease
US20140219986A1 (en) *	2011-03-11	2014-08-07	Amicus Therapeutics ,Inc.	Dosing regimens for the treatment of fabry disease
RS58718B1 (sr)	2011-05-12	2019-06-28	Proteostasis Therapeutics Inc	Regulatori proteostaze
ES2864774T3 (es) *	2011-12-22	2021-10-14	Centogene Ip Gmbh	Combinación de un compuesto que tiene la capacidad de reorganizar una enzima lisosomal y Ambroxol y/o un derivado de Ambroxol
WO2013112706A1 (en)	2012-01-25	2013-08-01	Proteostasis Therapeutics, Inc.	Proteasome activity modulating compounds
WO2014127038A1 (en) *	2013-02-12	2014-08-21	Baylor Research Institute	Methods and compositions related to calcium homeostasis and fabry disease
WO2015097088A1 (en) *	2013-12-23	2015-07-02	Bcn Peptides, S.A.	Bicalutamide analogs or (s)-bi calutam ide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis
US9675627B2 (en) *	2014-04-14	2017-06-13	Amicus Therapeutics, Inc.	Dosing regimens for treating and/or preventing cerebral amyloidoses
CA2955297C (en)	2014-07-25	2025-07-08	Takeda Pharmaceutical Company Limited	CRYSTALLINE STRUCTURE OF THE DOMAIN SIMILAR TO A HUMAN FOUR-PHOSPHATE ADAPTER PROTEIN 2 GLYCOLIPID TRANSFER PROTEIN
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
AU2017298376A1 (en) *	2016-07-19	2019-03-07	Amicus Therapeutics, Inc.	Treatment of Fabry disease in ERT-naive and ERT-experienced patients
US12020820B1 (en)	2017-03-03	2024-06-25	Cerner Innovation, Inc.	Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en)	2017-03-06	2022-05-17	Cerner Innovation, Inc.	Predicting glycogen storage diseases (Pompe disease) and decision support
PT4324522T (pt) *	2017-05-30	2026-03-13	Amicus Therapeutics Inc	Métodos de tratamento de pacientes com fabry tendo insuficiência renal
KR20220116305A (ko)	2017-05-30	2022-08-22	아미쿠스 세라퓨틱스, 인코포레이티드	신장 손상을 갖는 파브리 환자를 치료하는 방법
US11923048B1 (en)	2017-10-03	2024-03-05	Cerner Innovation, Inc.	Determining mucopolysaccharidoses and decision support tool
EP3749307B1 (en)	2018-02-06	2025-12-10	Amicus Therapeutics, Inc.	Use of migalastat for treating fabry disease in pregnant patients
PT3749308T (pt) *	2018-02-06	2024-01-25	Amicus Therapeutics Inc	Tratamento de pacientes com doença de fabry clássica com migalastato
EP3814336A1 (en)	2018-06-27	2021-05-05	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
AU2019295765B2 (en)	2018-06-27	2024-08-29	Yumanity, Inc.	Proteasome activity enhancing compounds
US20220184185A1 (en)	2018-07-25	2022-06-16	Modernatx, Inc.	Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP4289476A3 (en)	2018-08-20	2024-02-21	Amicus Therapeutics, Inc.	Methods of treating fabry disease in patients having a mutation in the gla gene
WO2021026447A1 (en)	2019-08-07	2021-02-11	Amicus Therapeutics, Inc.	Methods of treating fabry disease in patients having a mutation in the gla gene
US11191827B1 (en)	2020-12-09	2021-12-07	Tevogen Bio Inc.	COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US11623916B2 (en)	2020-12-16	2023-04-11	Amicus Therapeutics, Inc.	Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0463109A4 (en) *	1989-03-24	1992-11-19	Research Corporation Technologies, Inc.	Recombinant alpha-galactosidase, a therapy for fabry disease
CA2086413A1 (en)	1990-06-29	1991-12-30	Yohji Ezure	Piperidine derivatives
US6270954B1 (en)	1996-04-10	2001-08-07	The Regents Of The University Of California	Correction of genetic defects using chemical chaperones
US5900360A (en)	1996-04-10	1999-05-04	Welch; William J.	Correction of genetic defects using chemical chaperones
US6274597B1 (en)	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
US7842470B2 (en)	2001-10-09	2010-11-30	Oregon Health & Science University	Method for pharmacoperones correction of GnRHR mutant protein misfolding
PT2857036T (pt)	2003-01-31	2017-03-13	Mount Sinai School Of Medicine Of N Y Univ	Terapia combinada para o tratamento de distúrbios de deficiência proteica
US7446098B2 (en) *	2003-02-18	2008-11-04	Mount Sinai School Of Medicine Of New York University	Combination therapy for treating protein deficiencies
WO2004103368A1 (en)	2003-05-22	2004-12-02	The Hospital For Sick Children	Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
FR2861991B1 (fr)	2003-11-07	2008-01-18	Centre Nat Rech Scient	Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
BRPI0416216A (pt)	2003-11-12	2006-12-26	Amicus Therapeutics Inc	composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
AU2006247065B8 (en)	2005-05-17	2012-07-12	Amicus Therapeutics, Inc.	A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
US7973157B2 (en)	2005-06-08	2011-07-05	Amicus Therapeutics, Inc.	Imino and amino sugar purification
MX2007015602A (es)	2005-06-08	2008-02-21	Amicus Therapeutics Inc	Tratamiento de trastornos del sistema nervioso central asociados con mutaciones en genes que codifican las enzimas lisosomicas.
CA2616537A1 (en)	2005-07-27	2007-02-01	University Of Florida Research Foundation, Inc.	Small compounds that correct protein misfolding and uses thereof
WO2007089591A2 (en)	2006-01-27	2007-08-09	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for high throughput screening of pharmacological chaperones
JP2009537149A (ja)	2006-05-16	2009-10-29	アミークスセラピューティックスインコーポレイテッド	ファブリー病に対する治療の選択を診断し、評価するためのアッセイ
UA94624C2 (uk)	2006-09-22	2011-05-25	Крка, Товарна Здравіл, Д.Д., Ново Мєсто	Арипіпразолу геміфумарат і спосіб його одержання
MX2009010557A (es)	2007-03-30	2009-11-19	Amicus Therapeutics Inc	Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
WO2008134628A2 (en)	2007-04-26	2008-11-06	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en)	2007-04-26	2018-06-19	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en)	2008-02-12	2009-08-20	Amicus Therapeutics, Inc.	Method to predict response to pharmacological chaperone treatment of diseases
WO2010048532A1 (en)	2008-10-24	2010-04-29	Amicus Therapeutics, Inc.	Multiple compartment dosing model
WO2010138608A1 (en)	2009-05-26	2010-12-02	Amicus Therapeutics, Inc.	Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US9206457B2 (en)	2009-05-26	2015-12-08	Amicus Therapeutics, Inc.	Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
AR079057A1 (es)	2009-11-17	2011-12-21	Baylor Res Inst	Triaosilceramida urinaria (gb3) como marcador de enfermedad cardiaca
US20140219986A1 (en)	2011-03-11	2014-08-07	Amicus Therapeutics ,Inc.	Dosing regimens for the treatment of fabry disease
US10155027B2 (en)	2012-07-17	2018-12-18	Amicus Therapeutics, Inc.	Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
HK1209625A1 (en)	2012-07-17	2016-04-08	Amicus Therapeutics, Inc.	Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
KR20190087673A (ko)	2016-03-22	2019-07-24	아미쿠스 세라퓨틱스, 인코포레이티드	Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
AU2017298376A1 (en)	2016-07-19	2019-03-07	Amicus Therapeutics, Inc.	Treatment of Fabry disease in ERT-naive and ERT-experienced patients
TW201829770A (zh)	2017-01-10	2018-08-16	美商阿米庫斯醫療股份有限公司	用於治療fabry氏病之重組α-半乳糖苷酶A
KR20220116305A (ko)	2017-05-30	2022-08-22	아미쿠스 세라퓨틱스, 인코포레이티드	신장 손상을 갖는 파브리 환자를 치료하는 방법
WO2019017938A1 (en)	2017-07-19	2019-01-24	Amicus Therapeutics, Inc.	TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES
PT3675853T (pt)	2017-08-28	2022-11-28	Amicus Therapeutics Inc	Métodos para melhorar e/ou estabilizar a função cardíaca em pacientes com doença de fabry
EP3749307B1 (en)	2018-02-06	2025-12-10	Amicus Therapeutics, Inc.	Use of migalastat for treating fabry disease in pregnant patients
PT3749308T (pt)	2018-02-06	2024-01-25	Amicus Therapeutics Inc	Tratamento de pacientes com doença de fabry clássica com migalastato
EP4289476A3 (en)	2018-08-20	2024-02-21	Amicus Therapeutics, Inc.	Methods of treating fabry disease in patients having a mutation in the gla gene
BR112021024886A2 (pt)	2019-06-11	2022-01-25	Amicus Therapeutics Inc	Métodos de tratar a doença de fabry em pacientes com insuficiência renal
WO2021026447A1 (en)	2019-08-07	2021-02-11	Amicus Therapeutics, Inc.	Methods of treating fabry disease in patients having a mutation in the gla gene

2007
- 2007-05-16 JP JP2009511222A patent/JP2009537149A/ja active Pending
- 2007-05-16 EP EP12168451.8A patent/EP2533050B3/en active Active
- 2007-05-16 DK DK18197135.9T patent/DK3457135T3/da active
- 2007-05-16 MX MX2013006681A patent/MX351004B/es unknown
- 2007-05-16 SI SI200731457T patent/SI2533050T1/sl unknown
- 2007-05-16 ES ES14168748.3T patent/ES2573498T3/es active Active
- 2007-05-16 LT LTEP18197135.9T patent/LT3457135T/lt unknown
- 2007-05-16 CA CA2652553A patent/CA2652553C/en active Active
- 2007-05-16 DK DK12168451.8T patent/DK2533050T6/da active
- 2007-05-16 SI SI200732206T patent/SI3457135T1/sl unknown
- 2007-05-16 HU HUE14168748A patent/HUE027569T2/en unknown
- 2007-05-16 ES ES18197135T patent/ES3012794T3/es active Active
- 2007-05-16 EP EP07797506.8A patent/EP2024745B1/en active Active
- 2007-05-16 EP EP14168748.3A patent/EP2787345B8/en active Active
- 2007-05-16 AU AU2007253900A patent/AU2007253900A1/en not_active Abandoned
- 2007-05-16 SI SI200731776A patent/SI2787345T1/sl unknown
- 2007-05-16 EP EP24217103.1A patent/EP4541418A3/en active Pending
- 2007-05-16 WO PCT/US2007/069046 patent/WO2007137072A2/en not_active Ceased
- 2007-05-16 ES ES15173515T patent/ES2709445T3/es active Active
- 2007-05-16 FI FIEP18197135.9T patent/FI3457135T3/fi active
- 2007-05-16 US US11/749,512 patent/US7851143B2/en active Active
- 2007-05-16 PL PL18197135.9T patent/PL3457135T3/pl unknown
- 2007-05-16 PT PT121684518T patent/PT2533050E/pt unknown
- 2007-05-16 EP EP15173515.6A patent/EP2955520B1/en active Active
- 2007-05-16 MX MX2008014679A patent/MX2008014679A/es active IP Right Grant
- 2007-05-16 PT PT181971359T patent/PT3457135T/pt unknown
- 2007-05-16 PL PL14168748T patent/PL2787345T3/pl unknown
- 2007-05-16 DK DK14168748.3T patent/DK2787345T3/en active
- 2007-05-16 ES ES12168451.8T patent/ES2464527T7/es active Active
- 2007-05-16 EP EP18197135.9A patent/EP3457135B1/en active Active
- 2007-05-16 PL PL12168451T patent/PL2533050T6/pl unknown
- 2007-05-16 HU HUE18197135A patent/HUE071237T2/hu unknown
2010
- 2010-12-13 US US12/966,904 patent/US20110104727A1/en not_active Abandoned
2012
- 2012-04-12 US US13/445,338 patent/US9000011B2/en active Active
- 2012-12-27 JP JP2012285265A patent/JP6026268B2/ja active Active
2014
- 2014-05-27 CY CY20141100377T patent/CY1115180T1/el unknown
2015
- 2015-03-09 US US14/641,707 patent/US9480682B2/en active Active
- 2015-07-31 JP JP2015151795A patent/JP2016006088A/ja not_active Withdrawn
2016
- 2016-05-24 CY CY20161100448T patent/CY1117656T1/el unknown
- 2016-06-15 HK HK16106878.6A patent/HK1218955A1/en unknown
- 2016-10-31 US US15/338,923 patent/US9987263B2/en active Active
- 2016-11-11 NL NL300843C patent/NL300843I2/nl unknown
- 2016-11-15 CY CY2016040C patent/CY2016040I2/el unknown
- 2016-11-16 LT LTPA2016033C patent/LTC2787345I2/lt unknown
- 2016-11-16 HU HUS1600048C patent/HUS1600048I1/hu unknown
- 2016-11-16 LU LU93312C patent/LU93312I2/fr unknown
2018
- 2018-04-10 JP JP2018075570A patent/JP6800176B2/ja active Active
- 2018-05-08 US US15/974,217 patent/US10383864B2/en active Active
- 2018-05-08 US US15/974,222 patent/US10406143B2/en active Active - Reinstated
2019
- 2019-09-09 US US16/564,694 patent/US11241422B2/en active Active
2020
- 2020-07-27 JP JP2020126185A patent/JP7175297B2/ja active Active
2022
- 2022-02-07 US US17/665,969 patent/US20220160690A1/en active Pending
- 2022-11-08 JP JP2022178697A patent/JP2023027053A/ja active Pending
2024
- 2024-12-13 JP JP2024218337A patent/JP2025060691A/ja active Pending

Also Published As

Publication number	Publication date
DK2533050T3 (da)	2014-06-02
WO2007137072A2 (en)	2007-11-29
EP2955520A1 (en)	2015-12-16
PL2533050T3 (pl)	2014-08-29
EP2024745B1 (en)	2015-07-08
JP2025060691A (ja)	2025-04-10
HK1218955A1 (en)	2017-03-17
HUS1600048I1 (hu)	2017-01-30
EP4541418A2 (en)	2025-04-23
WO2007137072A3 (en)	2008-10-16
SI2533050T1 (sl)	2014-07-31
EP2024745A2 (en)	2009-02-18
EP2787345B1 (en)	2016-02-24
US20150238474A1 (en)	2015-08-27
EP2533050B3 (en)	2015-06-24
LTPA2016033I1 (lt)	2016-12-12
DK3457135T3 (da)	2025-02-24
JP2020196717A (ja)	2020-12-10
US20080056994A1 (en)	2008-03-06
US9987263B2 (en)	2018-06-05
CY1117656T1 (el)	2017-05-17
JP2023027053A (ja)	2023-03-01
MX2008014679A (es)	2009-04-14
AU2007253900A1 (en)	2007-11-29
JP2009537149A (ja)	2009-10-29
JP2016006088A (ja)	2016-01-14
US11241422B2 (en)	2022-02-08
EP4541418A3 (en)	2025-07-09
US20220160690A1 (en)	2022-05-26
DK2787345T3 (en)	2016-05-30
ES2709445T3 (es)	2019-04-16
US20190388409A1 (en)	2019-12-26
NL300843I2 (pl)	2016-12-21
EP2955520B1 (en)	2018-10-31
JP6800176B2 (ja)	2020-12-16
ES2464527T7 (es)	2015-09-14
MX351004B (es)	2017-09-26
LT3457135T (lt)	2025-05-12
US10383864B2 (en)	2019-08-20
CA2652553A1 (en)	2007-11-29
HK1178975A1 (en)	2013-09-19
PL3457135T3 (pl)	2025-06-09
PT3457135T (pt)	2025-02-04
CA2652553C (en)	2020-08-18
US9480682B2 (en)	2016-11-01
PL2533050T6 (pl)	2016-05-31
US10406143B2 (en)	2019-09-10
HK1129458A1 (en)	2009-11-27
LU93312I2 (fr)	2017-01-26
ES2573498T3 (es)	2016-06-08
JP6026268B2 (ja)	2016-11-16
HUE027569T2 (en)	2016-10-28
US7851143B2 (en)	2010-12-14
JP2013100307A (ja)	2013-05-23
CY2016040I1 (el)	2017-06-28
US20120220632A1 (en)	2012-08-30
CY2016040I2 (el)	2017-06-28
EP3457135A1 (en)	2019-03-20
EP2787345A1 (en)	2014-10-08
JP7175297B2 (ja)	2022-11-18
DK2533050T6 (da)	2015-09-21
ES3012794T3 (en)	2025-04-10
LTC2787345I2 (lt)	2017-10-10
EP2024745A4 (en)	2010-03-17
EP3457135B1 (en)	2024-12-04
PT2533050E (pt)	2014-05-26
CY1115180T1 (el)	2016-12-14
US9000011B2 (en)	2015-04-07
HUE071237T2 (hu)	2025-08-28
US20110104727A1 (en)	2011-05-05
ES2464527T9 (es)	2015-07-24
FI3457135T3 (fi)	2025-03-08
SI3457135T1 (sl)	2025-07-31
US20170042868A1 (en)	2017-02-16
EP2533050B1 (en)	2014-03-12
JP2018138564A (ja)	2018-09-06
SI2787345T1 (sl)	2016-08-31
US20180325881A1 (en)	2018-11-15
US20180250279A1 (en)	2018-09-06
EP2533050A1 (en)	2012-12-12
ES2464527T3 (es)	2014-06-03
EP2787345B8 (en)	2016-04-13

Publication	Publication Date	Title
PL2533050T3 (pl)	2014-08-29	Możliwości leczenia choroby Fabry'ego
GB0610680D0 (en)	2006-07-12	Therapeutic compounds
IL193678A0 (en)	2009-05-04	Therapeutic compounds
GB0602178D0 (en)	2006-03-15	Therapeutic treatment
ZA200900004B (en)	2009-12-30	Therapeutic compounds
GB0603041D0 (en)	2006-03-29	Therapeutic compounds
GB0624874D0 (en)	2007-01-24	Treatment
GB0711342D0 (en)	2007-07-25	Well treatment
GB0600692D0 (en)	2006-02-22	Well treatment
GB0606663D0 (en)	2006-05-10	Therapeutic compounds
GB0615809D0 (en)	2006-09-20	Therapeutic compounds
GB0612971D0 (en)	2006-08-09	Therapeutic compounds
GB0701456D0 (en)	2007-03-07	Treatment for respiratory disease
GB0607952D0 (en)	2006-05-31	Novel treatment
GB0625349D0 (en)	2007-01-31	Therapeutic compounds
GB0604460D0 (en)	2006-04-12	Treatment
GB0625345D0 (en)	2007-01-31	Therapeutic compounds
GB0603455D0 (en)	2006-04-05	Therapeutic compounds
GB0605573D0 (en)	2006-04-26	Therapeutic Compounds
GB0608269D0 (en)	2006-06-07	Therapeutic compounds
GB2439923B (en)	2011-04-06	Therapeutic compounds
GB0604130D0 (en)	2006-04-12	Treatment for skin disease
GB0610431D0 (en)	2006-07-05	Treatment
GB0605781D0 (en)	2006-05-03	Treatment
GB0600817D0 (en)	2006-02-22	Medical treatment